Therapy of Hepatocellular Carcinoma with Iodine-131-Lipiodol

Hojjat Ahmadzadehfar¹,*, Amir Sabet¹, Hans Jürgen Biersack¹ and Jörn Risse²

¹Department of Nuclear Medicine, University Hospital Bonn
²Radiology and Nuclear Medicine Institute, Bad Honnef
Germany

1. Introduction

Therapy in nuclear medicine practice has a long distinguished history. Nuclear medicine therapy is required to be highly specific and targeted, since it always involves administration of unsealed sources of radioactivity. Most therapy agents utilize β-particle emissions for their ability to penetrate tissues. This deposition of energy in tissue by β emitters results in cellular damage. Among the β emitters there are several choices with respect to energy of the β emission. Lower energy β particles can travel a few cell diameters, or at most in the sub-millimeter range. Higher energy β particles such as those emitted by Y-90 have an excellent tissue penetration with a range beyond the source of several millimeters. The physical half-life of the therapeutic radionuclide is an important consideration and underlying principle for therapy planning. Rarely, except in thyroid treatment, is the simple salt form of the radionuclide used. It is most likely attached to a drug or particle that controls its biodistribution. The ideal therapeutic radiopharmaceutical is one that remains attached to the parent drug or its metabolites, and is excreted rapidly through a known simple route¹.

For selected patients with HCC, confined to the liver but not amenable to resection or transplantation, both systemic and locoregional therapies can be considered. These include

1. Percutaneous interventions (ethanol injection, radiofrequency thermal ablation),
2. Transarterial interventions
   a. Embolization (TAE), chemoperfusion (TAC), or chemoembolization (TACE),
   b. Radioembolization (RE) or radioactive agent perfusion such as 131Iodine-Lipiodol or 188RE-Lipiodol
3. External radiation therapy and
4. Chemotherapy, including gene and immune therapy.

In this chapter we focus only on the therapeutic indications, usefulness and methods of treatment with 131-Iodine Lipiodol (131I-Lipiodol). Its rationale comes from the anatomical

* Corresponding Author
and physiological aspects of HCC being exploited for the delivery of the therapeutic agent. The liver has a dual blood supply: the hepatic artery and the portal vein. Observations on vascular supply to hepatic malignancies have demonstrated that metastatic hepatic tumours >3 mm derive in contrast to healthy hepatic cells 80–100% of their blood supply from the arterial rather than the portal hepatic circulation.

2. Basic characteristics of 131 I-Lipiodol

131I is a beta emitting radionuclide with a physical half life of 8.04 days. The maximum and mean beta particle energies are 0.61MeV and 0.192MeV respectively. Additionally, 131I emits a principal gamma photon of 364 keV (81% abundance). The Beta radiation of I131 is responsible for its therapeutic effects while gamma radiation makes the distribution of the radiopharmaceutical visible.

Lipiodol is a mixture of iodized esters of poppy seed oil fatty acids used as a contrast medium for the detection of HCC which remains in these tumours for a longer period compared to normal liver or in other tissues. Isotopic exchange is used to label iodine-rich Lipiodol with 131I (Lipiocis®, CIS Bio International/ member of IBA group). Lipiocis® is licensed in France for the treatment of patients with HCC and portal vein thrombosis (PVT). It was developed in the 1990s and was the first radiolabeled vector to be used in this setting. According to biodistribution data, more than 75% of the 131I-Lipiodol stays following the arterial administration in the liver and the remainder reaches the lungs. Other tissues, including the thyroid gland, receive very little radiation.

An in vitro assessment showed an unspecific uptake of Lipiodol in non-malignant endothelial cells apart from its concentration in cancer cell lines. Lipiodol alone does not appear to have any cytotoxic effect against any of the studied cell lines. However, 131I-Lipiodol is highly and only selectively cytotoxic for the cancer cell lines. Inability of tumourous cells unlike non-malignant ones to expel Lipiodol, revealed by quantification methods using computer-assisted image analysis, may further enhance the cytotoxic effect of 131I-Lipiodol in cancer cells. There is no separation of the 131I from Lipiodol during the uptake process by the cancer cells, as Lipiodol is a naturally iodinated oil compound with an iodine content of 38–40%. 131I-Lipiodol shows cytotoxic effects against the cancer cell lines even in doses as small as a quarter of the radioactivity of the 131I alone.

The tumour/ non tumour uptake ratio is about 15–20:1 and increases with time, while the effective half life within the HCC tissue is also longer than that in healthy tissues (almost 6 days versus 4 days). Generally, more than 10 % of the injected Lipiodol remains within the tumour. The retention of 131I-Lipiodol in HCC tumours after intra-arterial infusion is related not only to embolization in the micro vessels of the tumour, but also to the entry into the interstitium and the tumour cells themselves. This retention can be assessed by tomodensitometric examination and inversely relates to the tumour size. Indeed, 88% of the HCCs smaller than 5 cm exhibit a high retention (of type 3 or 4 according to the criteria of Maki et al.) whereas 74% of the HCCs larger than 10 cm exhibit only a weak retention of less than 50% (of type 1 or 2 according to the criteria of Maki). Moreover, the clearance of Lipiodol from the tumour lasts longer than from the normal liver or from the lungs, possibly because of a lack of macrophagic cells in the tumour. 131I-Lipiodol is eliminated mainly
through the urinary tract, reaching 30–50% of the injected activity at day 8, but also to a small extent by way of the faeces (<3% at day 5) \(^4\).

The required therapy activity for the intended tumour dose can be calculated for a given tumour mass according to its size. For instance producing 120 Gy in a tumour with a diameter of 1 cm requires less than 3 MBq I-131 while the same dose in a tumour with a fivefold larger diameter requires hundredfold more activity \(^10\).

The radionuclide is supplied in 2 ml solution for injection and stored in a 4 ml cone shaped glass vial. The specific activity at calibration date is 1.1 GBq/ml and its shelf life from this time is 3 days \(^11,12\).

The conjunction of lipiodol with TACE, also called TOCA (transarterial oily chemoembolization), has also been used allowing the delivery of locally concentrated therapy due to the selective retention of the agent in the tumours for an extended period \(^13\).

### 3. Basics of interventional nuclear medicine therapies of HCC with I\(^{131}\)-Lipiodol

Radiation is tumoricidal if sufficient doses can be delivered selectively to the tumour without damaging adjacent normal tissue \(^14\). Normal hepatocytes have a lower tolerance to the effects of radiation than neoplastic tissue. The dose required to destroy solid tumors, estimated at ≥70 Gy, is far greater than the liver tolerance dose of 35 Gy when delivered to the whole liver in 1.8 Gy/d fractions \(^15\). If the whole liver is exposed to external-beam radiation at a mean radiation dose of 43 Gy, more than 50% of patients develop liver dysfunction \(^16\). Conformal and stereotactic radiation therapy techniques can be used to deliver much higher radiation doses in cases with focal involvement \(^17\); however, since primary neoplasms are often multifocal and irregular in shape and potentially replace large parts of the liver volume, only a small minority of patients are optimal candidates for such therapies \(^18\). Internal radiation aims at improving the selectivity of the radiation by targeting the radioisotopes to the tumour cells. To achieve this targeting, the therapeutic radiopharmaceuticals such as 90Y microspheres or 131I-Lipiodol may be administered via the hepatic artery \(^19\).

Based on studies considering biodistribution of intraarterial 131I-Lipiodol in humans \(^4,20,21\), radiation doses for every mCi (37 MBq) of administered activity were estimated to be 31 cGy for the normal liver, 22 cGy for the lungs, and 239 cGy for a tumor with a greatest diameter of 4 cm using the formula:

$$\text{Dose (cGy)} = 73.8 \times E \times T_e \times \frac{A_0}{M} + 0.0346 \times \Gamma \times g \times \frac{A_0}{M}$$

where \(E\) is the average beta energy (MeV), \(T_e\) is the effective half-life (days), \(\Gamma\) is the specific gamma ray constant (cGy cm\(^2\)/mCi hr), \(A_0\) is the initial activity (µCi), \(M\) is the mass(g), and \(g\) is the geometric factor (cm).

### 4. Contraindications

Absolute contraindications

1. Pregnancy and breastfeeding, 2. life expectancy less than 1 month, 3. hepatic encephalopathy, 4. tumour Stage OKUDA III\(^{11,12}\).
Relative contraindications

1. High extrahepatic tumor burden, 2. acute or severe chronic pulmonary disease, 3. The presence of contraindications for hepatic artery catheterisation.\textsuperscript{11, 12}

5. Therapeutic indications for 131I-Lipiodol

5.1 Palliative treatment of inoperable hepatocellular carcinoma

An improved survival rate is readily documented for those treated with 131I-Lipiodol, comparing to those receiving only medical support.\textsuperscript{22} The treatment is more effective for small, solitary and well encapsulated tumors and the response rate decreases with increasing tumor size. Its main limitation is its ineffectiveness in large (>5 cm) tumors. However, transarterial therapy with 131I-Lipiodol is superior to systemic therapy in tumours up to 5 cm in diameter.\textsuperscript{23}

The data on therapy efficacy have remained non-uniform. A decrease in tumour size has been reported in about 50% to 60% of patients; two early studies with seven and nine patients showed response in all tumours.\textsuperscript{24, 25} In larger studies classifying therapy success according to the WHO criteria, the response rate decreases to about 30%.\textsuperscript{26} This is in agreement with our own data.\textsuperscript{27} Reported response rates in different studies are summarised in table 1; only reports with more than ten patients, data on changes in tumour size and follow-up studies of at least one month, are considered.

<table>
<thead>
<tr>
<th>First author, year, reference</th>
<th>Number of evaluable patients</th>
<th>CR</th>
<th>PR</th>
<th>MR</th>
<th>SD</th>
<th>PD</th>
<th>AFP decrease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yoo 1991\textsuperscript{29}</td>
<td>24</td>
<td>0</td>
<td>3</td>
<td>5</td>
<td>8</td>
<td>8</td>
<td>13/16</td>
</tr>
<tr>
<td>Raoul 1992\textsuperscript{30}</td>
<td>30</td>
<td>0</td>
<td>18</td>
<td>4</td>
<td>6</td>
<td>2</td>
<td>22/29</td>
</tr>
<tr>
<td>Leung 1994\textsuperscript{31}</td>
<td>22</td>
<td>1</td>
<td>3</td>
<td></td>
<td>12</td>
<td>6</td>
<td>13/25</td>
</tr>
<tr>
<td>Bhattacharya 1995\textsuperscript{32}</td>
<td>22</td>
<td>0</td>
<td>7</td>
<td></td>
<td>8</td>
<td>7</td>
<td>2/22</td>
</tr>
<tr>
<td>Raoul 1997\textsuperscript{28}</td>
<td>25</td>
<td>1</td>
<td>15</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>20/40</td>
</tr>
<tr>
<td>De Baere 1999\textsuperscript{26}</td>
<td>23</td>
<td>0</td>
<td>3</td>
<td></td>
<td>12</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Risse 2000\textsuperscript{27}</td>
<td>13</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Rindani 2002\textsuperscript{33}</td>
<td>12</td>
<td>0</td>
<td>6</td>
<td></td>
<td>5</td>
<td>1</td>
<td>5/7</td>
</tr>
<tr>
<td>Borbath 2005\textsuperscript{34}</td>
<td>19</td>
<td>1</td>
<td>0</td>
<td></td>
<td>7</td>
<td>11</td>
<td>2/24</td>
</tr>
<tr>
<td>Risse 2006\textsuperscript{35}</td>
<td>17</td>
<td>0</td>
<td>4</td>
<td>1</td>
<td>7</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Boucher 2007\textsuperscript{36}</td>
<td>40</td>
<td>1</td>
<td>18</td>
<td></td>
<td>19</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

CR: complete response, PR: partial response (tumour reduction > 50%), MR: minimal response (tumor reduction between 25 an 50%), AFP alpha-fetoprotein, SD: stable disease (tumour size change between -25 % - +25 %), PD: progressive disease (tumour increase > 25 %)

Table 1. Efficacy of 131I-Lipiodol therapy in patients with unresectable HCC
131I-Lipiodol is also comparatively favourable to other regional therapy procedures for palliative treatment of HCC. A multicentre randomised trial by Raoul et al \(^2\&\) showed that 131I-Lipiodol therapy \((n=73)\) was associated with a better patient tolerance and fewer vascular complications than TACE \((n=69)\), although no survival advantage was demonstrated\(^2\&\).

In a published study from our group 38 courses of intra-arterial 131I-Lipiodol therapy with a total activity up to 6.7 GBq were performed in 18 patients with HCC \((6\) with PVT)\(^3\&\). Tumour volume decreased in 20/32 index nodules \((63\%)\) after the first course. Repeated therapy frequently resulted in further tumour reduction. Partial response was seen in 11 nodules while 4 nodules showed a minor response. Stable disease was found in 12 patients and progressive disease in 5. Significant response was associated with pre-therapeutic nodule volume up to 150 ml \((\text{diameter of } 6.6 \text{ cm})\). Survival rate after 3, 6, 9, 12, 24 and 36 months was 78, 61, 50, 39, 17, and 6\% respectively. Matched-pairs analysis of survival revealed 131I-Lipiodol to be superior to medical treatment. The most important side effect was a pancreatitis-like syndrome while overall tolerance was very acceptable.

The median survival in patients with unresectable HCC undergoing 131I-Lipiodol therapy has been reported between 7 and 27 months \(^3\&\, 36\text{-}38\). Chua et al reported the factors associated with survival in a newly published study including the AJCC stage \((1\text{-}2 \text{ vs } 3\text{-}4)\), Barcelona Clinic Liver Cancer stage \((A\text{-}B \text{ vs } C)\), Cancer of the Liver Italian Program score \((< 2 \text{ vs } >2)\), maximum tumor size \((<4 \text{ vs } >4 \text{ cm})\), extrahepatic disease, previous surgery and response to treatment \((\text{favorable vs unfavourable})\)\(^3\&\). Considering response rate, AJCC stage 1-2 and Cancer of the Liver Italian Program score \(< 2\) were found to be independent predictors for a favorable response in this study\(^3\&\).

### 5.1.1 Palliative treatment of HCC with Portal vein thrombosis (PVT)

Although the PVT prohibits any attempt of TACE, 131I-Lipiodol has proved to be an effective therapy option in patients with HCC and PVT\(^3\&\). Raoul et al. compared 131I-Lipiodol therapy and best supportive care in patients with HCC and PVT. The survival rates at 3, 6 and 9 mo was 71\%, 48\% and 7\% for the treated group; and 10\%, 0\% and 0\% for the group receiving only supportive care. The authors concluded that 131I-Lipiodol is a safe and effective palliative treatment of HCC in the presence of portal vein thrombosis \(^2\&\). However it should be noted that radioembolization \((\text{RE})\) with 90Y-Microspheres has proved to be a feasible alternative treatment for HCC patients with PVT as discussed in following section.

### 5.1.2 131I-Lipiodol versus radioembolisation with 90Y-Microspheres

90Y radioembolization \((\text{RE})\), or selective internal radiation therapy \((\text{SIRT})\), is a promising catheter-based liver-directed modality approved by the Food and Drug Administration for patients with primary and metastatic liver cancer\(^4\). In a meta-analysis of 14 published articles Venti et al showed almost 80\% any response \((\text{AR} = \text{[CR} + \text{PR} + \text{SD})\) for a total of 325 patients with HCC. According to this meta-analysis, treatment with resin microspheres was associated with a significantly higher proportion of AR than with glass microsphere \((0.89 \text{ vs } 0.78 [P <0.02])\)\(^4\).

Although RE is currently the preferred method for treating HCC compared to 131I-Lipiodol, its embolic nature makes severe liver dysfunction a theoretic contraindication for this
technique, as in TACE. In addition, techniques using 90Y-labeled products tend to cost up to 10 times more than therapy with 131I-Lipiodol, affecting the therapeutic approach especially in the countries with a poor insurance system.

PVT is not an absolute contraindication for RE any more. Although resin microspheres could pose the patient at risk for significant liver dysfunction based on the embolic treatment effect, therasphere has been shown to be safe even when the portal vein has been invaded by tumor. However, recent studies describe safe performance of RE with resin microspheres even in PVT. There is no prospective study which compares these two methods (RE vs 131I-Lipiodol) in patients with PVT in HCC considering response rate, time-to-progression, and survival.

5.1.3 131I-Lipiodol-therapy versus TAE and TACE

131I-Lipiodol therapy in patients with cirrhosis and HCC has an efficacy similar to that of TACE/TAE therapy. However 131I-Lipiodol appears to be of more benefit in patients with advanced disease, for example, in those with Okuda stage III disease or BCLC stage D as well as in patients with PVT. PVT patients receiving 131I-Lipiodol lived on average almost a year longer than those treated with TACE or TAE. Moreover, 131I-Lipiodol is much better tolerated than chemoembolization, both in terms of clinically expressed side effects and arteriographic findings.

5.2 Performing 131I-Lipiodol as an adjuvant or neo-adjuvant therapy

Early intrahepatic recurrence is common after curative resection of hepatocellular carcinoma, frequently due to microscopic metastatic disease or less commonly, metachronous multicentric carcinoma within the liver remnant not detected before or during resection by conventional imaging and has led to attempts at adjuvant or neoadjuvant therapies.

5.2.1 131I-Lipiodol as an adjuvant therapy

It has been thought that when the postsurgical liver starts to regenerate, small microscopic daughter tumours can be stimulated to grow. If these were pre-cleared the chances of a recurrence would be lowered. Thus, 131I-Lipiodol has been used in an adjuvant setting after curative surgical resection. A single dose of 1.85 GBq 131I-Lipiodol administered 6 weeks after curative resection of hepatocellular carcinoma could significantly decrease the rate of recurrence and increased disease-free and overall survival in a study by Lau et al. These findings were also confirmed by Boucher et al. administering 2.4 GBq 131I-Lipiodol 8-12 weeks after surgery. NG et al. also reported a good overall survival with 1.7 GBq 131I-Lipiodol 1-8 months after surgery. It seems that there is no clinically significant adverse effect of adjuvant therapy by intra-arterial 131I-Lipiodol after curative liver resection for HCC. These results were also confirmed in a recent published study from Chua et al. It is necessary to perform more randomized controlled trials with more patients to confirm the role of 131I-Lipiodol as an adjuvant treatment especially considering the timing and the administered dose.
5.2.2 Neo-adjuvant 131I-Lipiodol administration before liver transplantation/resection

In a study by Raoul et al.,

curative resection of hepatocellular carcinoma or liver transplantation was preceded by 2 injections of 2.4 GBq 131I-Lipiodol (5 weeks preoperative) to reduce intrahepatic recurrence. The procedure was well tolerated and associated with an objective tumour response in 56% and a complete histological response in 24% of 34 treated patients. An objective tumour response or necrosis of more than 90% of the tumour mass was observed in three-quarters of these patients. Brans et al. treated 10 HCC patients with almost 1.8 GBq 131I-Lipiodol in a pilot study followed by liver transplantation within 1–9 months. The evidence of an anti-tumoural effect of 131I-Lipiodol was observed in 50% of patients. However, performing randomized comparisons between surgery alone versus surgery after intra-arterial injection of 131I-labelled Lipiodol in patients with large but technically resectable tumours is needed.

6. Imaging before performing the therapy

The work-up includes a three-phase contrast computed tomography (CT) and gadolinium-enhanced magnetic resonance imaging (MRI) of the liver for the assessment of tumour and non-tumour volume, portal vein patency, and the extent of extra-hepatic disease. Although FDG-PET is suitable for tumours showing high glucose metabolism such as colorectal carcinoma, melanoma, head and neck, and breast cancers, malignancies such as HCC or neuroendocrine tumours, except for their aggressive types show no or a very low-grade FDG uptake. The suboptimal sensitivity of FDG-PET for the detection of HCC, ranging between 50% and 70% makes it an unsatisfactory imaging choice for the pre- and post-treatment evaluation in this group of patients; however, it adds valuable prognostic information (metabolic grading) as patients with a negative FDG-PET show a better prognosis than those with high FDG uptake. Choline PET/CT may also play a role in imaging of specific types of HCC in the near future.

7. Intervention technique

Treatment with 131I-Lipiodol serves as an example for multidisciplinary management including the patient selection and care, the detailed anatomical study and dose calculation, the post-interventional treatment including timing and selection of systemic treatment, adequate follow-up of the patient as well as the management of possible complications. Prior to the therapy, patients should receive both written and verbal information about the procedure and the palliative nature of the treatment. The renal functional status should be adequate for the use of contrast agents during the pre-therapeutic angiogram. Haemodialysis patients may be treated with 131I-Lipiodol, however, dialysis has to be planned and timed before and after the intervention. Patients should be given a peri-interventional drug regimen with slow intravenous infusion of 24 mg dexamethasone and 8 mg ondansetron during the whole procedure and intraarterial injection of 50 mg pethidine immediately before application of the radiopharmaceutical. After blocking the thyroid with perchlorate, diagnostic angiography of the liver vessels should be performed with special attention to collateral arteries to other organs. Occasionally, computed tomography with arterioportography (CT-AP) via the catheter could be added, partly with the injection of
small amounts of “cold” Lipiodol (Guerbet®). In patients with “normal” hepatic arterial anatomy the catheter can be positioned in the main hepatic artery for nonselective injection of 131I-Lipiodol. In cases with multiple nodules or variable arterial blood supply, the liver lobe containing the largest tumour mass is treated in the first session and the remaining masses in the following ones.

Fig. 1. Quantitative whole body scintigraphy obtained 7 days post therapeutic in a 52-year-old man showing significant activity in the HCCs and only a faint lung uptake.
131I-Lipiodol (2.22 GBq in 2 ml / ampulla) should be prepared in an appropriately ventilated cabinet in the department of Nuclear Medicine to avoid radioiodine aerosol inhalation. Injection should take at least some minutes to ensure good tolerance by the patient. The procedure and special radiation protection measures have been readily published in detail. The applied activity should be determined as the difference between activity in the last receptacle before injection and the remaining activity of last receptacle and the catheter-system after flushing with saline. After the procedure the patients are transferred to the station and isolated until radiation exposure to their environment becomes low enough to be discharged (e.g in Germany < 1mSv/year).

Dexamethasone and tamoxifen could increase the tumoral uptake of Lipiodol and could be combined with 131I-Lipiodol to improve the therapy effectiveness.

Fig. 2. SPECT/CT of the liver could be used for a better quantification of the radioactive distribution as well as dosimetry simultaneously. Note the distribution of 131I-Lipiodol in the HCCs showed with arrow.
For certain patients, in particular those presenting with a relatively large tumour several injections in 2-3 months interval may be necessary to obtain an effective response.

As Garin et. al. stated, nuclear medicine specialist receives an average dose between 140 and 443 µSv at the level of the fingers(according to the fingers) and about 17 µSv at the thorax. For the radiologists, the average doses received are 215 µSv and 15 µSv at the level of the fingers and at the thorax respectively. The authors showed that the administration of high therapeutic activities of 131I-Lipiodol can be carried out with a dose much lower than the European regulatory limit of 500 mSv at the level of the fingers for the exposed personnel.

8. Follow-up

Definitions of the appropriate length of the follow-up and the time points required for technical success are not well established and post treatment follow-up schedules vary depending on the treatment plan of each patient. For the evaluation of response, abdominal imaging should be performed 4 weeks and 2-3 months after each therapy. Follow-up should be performed with the same modality used pre-therapeutic such as MRI, 3 phase CT, 18F-FDG, 11C-/18F-Cholin or 11C-/18F-Acetate PET/CT. AFP should be tested for patients with initially increased AFP.

9. Dosimetry

Becker et al. performed a dosimetric evaluation using SPECT/CT, applied to a series of 41 patients who received one or more injections of 131I-Lipiodol for treatment of HCC using a standard activity of 2220 MBq. They found a mean tumoural absorbed dose of 248±176 Gy for the first treatment, compared with 152±122 Gy for the second treatment, and pointed out a correlation between the tumoural absorbed dose, calculated in tomographic mode, and morphological response to first treatment alone. These results pleaded in favour of increasing the administered activity at the first treatment. A tumoral absorbed dose of 280 Gy was found to represent an effective threshold absorbed dose. While 84% of the patients above this value were responders, no one appeared to respond at lower absorbed doses. Tumour response adversely correlates with tumour size. High response rates have been found in tumour nodes with diameters below 6 cm in which an absorbed dose of up to 288 Gy has been calculated. However, it must be considered that a reduction in tumour mass does not necessarily correlate with improved survival.

10. Safety of 131I-Lipiodol therapy

A phase I study and a multi centric phase II trial could not demonstrate any specific toxic effects of 131I-Lipiodol. The main limiting factor was the long patient isolation required for the purpose of radioprotection. Consequently, a fixed injected activity of 2.2 GBq is proposed as a good compromise to achieve the desired efficacy while reducing the hospital stay to 1 week. Serious adverse effects are very rare. Undesirable effects observed fairly frequently consist of moderate and temporary fever (29%), moderate and temporary disturbances of the biological liver test (20%) and hepatic pain on injection (12.5%).

Moderate and reversible leukopenia (7%) and serious interstitial pneumopathies (2%) are observed more rarely. Interstitial pneumonia has been reported in an estimated
prevalence of 15.5 cases per 1000 treated patients with a median respiratory symptoms delay of 30 days\textsuperscript{61}.

Some authors have expressed their concern about hypothyroidism despite the very low thyroid uptake \textsuperscript{62}. Using potassium iodide premedication can significantly decrease thyroid iodide uptake and consequently probability of hypothyroidism \textsuperscript{63}.

11. Conclusion

The effectiveness of 131I-Lipiodol treatment is proven both in the treatment of HCC with portal thrombosis and as an adjuvant to surgery after the resection of HCCs. It is at least as effective as chemoembolization and is tolerated much better. Severe liver dysfunction represents theoretic contraindication for radioembolization as well as for TACE. In such cases 131I-Lipiodol is an alternative therapy option especially in tumors smaller than 6 cm.

12. References


Therapy of Hepatocellular Carcinoma with Iodine-131-Lipiodol


This book covers the clinical aspects of hepatocellular carcinoma. This book is a compendium of papers written by experts from different parts of the world to present the most up-to-date knowledge on the clinical aspects of hepatocellular carcinoma. This book is divided into three sections: (I) Diagnosis / Differential Diagnosis; (II) Surgical Treatment; (III) Non-surgical Treatment. There are 19 chapters covering topics from novel diagnostic methods to hepatic lesions mimicking hepatocellular carcinoma, from laparoscopic liver resection to major hepatectomy without allogeneic blood transfusion, from molecular targeted therapy to transarterial radioembolization, and from local ablative therapy to regional therapy. This volume is an important contribution to the clinical management of patients with hepatocellular carcinoma. The intended readers of this book are clinicians who are interested in hepatocellular carcinoma, including hepatologists, liver surgeons, interventional and diagnostic radiologists, pathologists and epidemiologists. General surgeons, general physicians, trainees, hospital administrators, and instruments and drug manufacturers will also find this book useful as a reference.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.